A novel click chemistry-based, universal radiolabelling platform revolutionizing the generation of theranostic radiopharmaceuticalsbroad
TETRAKIT · Horizon Europe grant · 2025-07-01–2027-06-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2024-ACCELERATOROPEN-01. CORDIS record →
Objective
TetraKit Technologies (TT) is developing the TetraKit Platform, a universal radiolabelling platform that enables the synthesis of novel therapeutic and diagnostic (theranostic) radiopharmaceuticals (RPs). By overcoming the limitations of currently available radiochemistry solutions, TT will address the unmet need for an innovative approach that makes radiolabeling, specifically with radiohalogens, simple, rapid, effective and scalable. Based on an ultrafast next generation tetrazine ligation and linker technology, the TetraKit Platform allows labelling of any biomolecule (target vector) with any radiohalogen or radiometal, according to a versatile ‘plug-and-play’ principle. As such, TT will facilitate unleashing the full potential of novel theranostic RPs to serve the need of millions of cancer patients worldwide.To validate the TetraKit Platform, TT seeks EIC Accelerator blended financing to advance the clinical development of the lead asset emerging from the platform, 131I-DualFAPi, an iodine-131-labelled therapeutic RP that targets the fibroblast activation protein (FAP) – THE ‘next billion-dollars theranostics target’. Initially to be developed for the treatment of metastasized Triple Negative Breast Cancer (TNBC), an aggressive type of cancer with poor survival chances, TT’s lead asset will be the first radiohalogenated FAP-targeting therapeutic RP in clinical development, made possible by the TetraKit Platform. Completion of a Phase 1/2 program in TNBC patients will present a significant value inflection point for TT, which is anticipated to result in a strategic partnership for the final development and commercialization steps. Successful development of 131I-DualFAPi will be an essential milestone that will allow TT to fully exploit the TetraKit Platform, bringing immense commercial and societal value.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| TETRAKIT TECHNOLOGIES APS | DK | coordinator | €2,458,700 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.